Asset Details
Do you wish to reserve the book?
Effect of a Strict ‘No-Talking’ Policy During Intravitreal Injection on Post-Injection Endophthalmitis
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Effect of a Strict ‘No-Talking’ Policy During Intravitreal Injection on Post-Injection Endophthalmitis
Do you wish to request the book?
Effect of a Strict ‘No-Talking’ Policy During Intravitreal Injection on Post-Injection Endophthalmitis
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Effect of a Strict ‘No-Talking’ Policy During Intravitreal Injection on Post-Injection Endophthalmitis
2015
Overview
BACKGROUND AND OBJECTIVE:
To report the effect of a “no-talking” policy during intravitreal injection (IVI) on post-injection endophthalmitis.
PATIENTS AND METHODS:
Retrospective, comparative, consecutive case series of patients receiving IVI between Jan. 1, 2009, and Dec. 31, 2012. A 24-month “usual care” period was compared to a 24-month no-talking period, during which a strategy to further minimize speech during IVI was implemented.
RESULTS:
During the usual care period, 47,155 IVIs were performed, with nine culture-positive cases (0.019%), including seven due to oral pathogens (0.015%). During the no-talking period, 82,658 IVIs were performed, with eight culture-positive cases (0.010%), including two due to oral pathogens (0.002%). The no-talking policy was associated with a decreased endophthalmitis risk (During the usual care period, 47,155 IVIs were performed, with nine culture-positive cases (0.019%), including seven due to oral pathogens (0.015%). During the no-talking period, 82,658 IVIs were performed, with eight culture-positive cases (0.010%), including two due to oral pathogens (0.002%). The no-talking policy was associated with a decreased endophthalmitis risk (
P
= .004), including oral pathogen-associated endophthalmitis (
P
= .02).
CONCLUSION:
This study demonstrates that a more stringent no-talking policy during IVI may reduce the risk of post-injection endophthalmitis.
[[
Ophthalmic Surg Lasers Imaging Retina
. 2015;46:1028–1034.]
Publisher
SLACK INCORPORATED
Subject
/ Angiogenesis Inhibitors - therapeutic use
/ Anti-Bacterial Agents - therapeutic use
/ Bacteria - isolation & purification
/ Bevacizumab - therapeutic use
/ Endophthalmitis - epidemiology
/ Endophthalmitis - microbiology
/ Endophthalmitis - prevention & control
/ Eye Infections, Bacterial - epidemiology
/ Eye Infections, Bacterial - microbiology
/ Eye Infections, Bacterial - prevention & control
/ Female
/ Humans
/ Male
/ Practice Patterns, Physicians
/ Ranibizumab - therapeutic use
/ Receptors, Vascular Endothelial Growth Factor - therapeutic use
/ Recombinant Fusion Proteins - therapeutic use
/ Talking
/ Vascular Endothelial Growth Factor A - antagonists & inhibitors
